Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study - PubMed (original) (raw)

Clinical Trial

doi: 10.1159/000331065. Epub 2011 Aug 22.

• PMID: 21934349
• DOI: 10.1159/000331065

Clinical Trial

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study

Annekathrin Roth et al. Onkologie. 2011.

No abstract available

PubMed Disclaimer

Similar articles

• A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
  Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T. Furuse J, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):113-20. doi: 10.1007/s00280-009-1011-z. Epub 2009 Apr 29. Cancer Chemother Pharmacol. 2009. PMID: 19404641 Clinical Trial.
• Time to move to targeted drugs in biliary tract cancer?
  Louvet C, Tournigand C. Louvet C, et al. Onkologie. 2010;33(1-2):10-1. doi: 10.1159/000271544. Epub 2010 Jan 22. Onkologie. 2010. PMID: 20164655 No abstract available.
• BGJ398 for FGFR-altered advanced cholangiocarcinoma.
  Gilbert JA. Gilbert JA. Lancet Oncol. 2018 Jan;19(1):e16. doi: 10.1016/S1470-2045(17)30902-6. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29233557 No abstract available.
• Photodynamic therapy in cholangiocarcinomas.
  Ortner MA. Ortner MA. Best Pract Res Clin Gastroenterol. 2004 Feb;18(1):147-54. doi: 10.1016/S1521-6918(03)00100-8. Best Pract Res Clin Gastroenterol. 2004. PMID: 15123089 Review.
• Clinical presentation and management of intrahepatic cholangiocarcinoma.
  Farges O, Fuks D. Farges O, et al. Gastroenterol Clin Biol. 2010 Mar;34(3):191-9. doi: 10.1016/j.gcb.2010.01.006. Epub 2010 Mar 4. Gastroenterol Clin Biol. 2010. PMID: 20202770 Review. No abstract available.

Cited by

• Therapeutic options for intrahepatic cholangiocarcinoma.
  Bupathi M, Ahn DH, Bekaii-Saab T. Bupathi M, et al. Hepatobiliary Surg Nutr. 2017 Apr;6(2):91-100. doi: 10.21037/hbsn.2016.12.12. Hepatobiliary Surg Nutr. 2017. PMID: 28503556 Free PMC article. Review.
• Second-line systemic treatment for advanced cholangiocarcinoma.
  Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Rogers JE, et al. J Gastrointest Oncol. 2014 Dec;5(6):408-13. doi: 10.3978/j.issn.2078-6891.2014.072. J Gastrointest Oncol. 2014. PMID: 25436118 Free PMC article.
• Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
  Fraveto A, Cardinale V, Bragazzi MC, Giuliante F, De Rose AM, Grazi GL, Napoletano C, Semeraro R, Lustri AM, Costantini D, Nevi L, Di Matteo S, Renzi A, Carpino G, Gaudio E, Alvaro D. Fraveto A, et al. PLoS One. 2015 Nov 16;10(11):e0142124. doi: 10.1371/journal.pone.0142124. eCollection 2015. PLoS One. 2015. PMID: 26571380 Free PMC article.
• Activation of abl family kinases in solid tumors.
  Ganguly SS, Plattner R. Ganguly SS, et al. Genes Cancer. 2012 May;3(5-6):414-25. doi: 10.1177/1947601912458586. Genes Cancer. 2012. PMID: 23226579 Free PMC article.
• Comparative Proteomic Analysis of the Mesenchymal Stem Cells Secretome from Adipose, Bone Marrow, Placenta and Wharton's Jelly.
  Shin S, Lee J, Kwon Y, Park KS, Jeong JH, Choi SJ, Bang SI, Chang JW, Lee C. Shin S, et al. Int J Mol Sci. 2021 Jan 15;22(2):845. doi: 10.3390/ijms22020845. Int J Mol Sci. 2021. PMID: 33467726 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • S. Karger AG, Basel, Switzerland

• Medical

  • MedlinePlus Health Information